- Conditions
- Breast Cancer, Colorectal Cancer, Ovarian Cancer, Non-Small Cell Lung Cancer, Acral Lentiginous Melanoma, Head and Neck Squamous Cell Carcinoma, Hepatocellular Carcinoma, Esophageal Squamous Cell Carcinoma, Urothelial Carcinoma, DMMR Colorectal Cancer, MSI-H Colorectal Cancer, Melanoma, Platinum-Resistant Primary Peritoneal Carcinoma, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Epithelial Ovarian Cancer, Triple Negative Breast Cancer
- Interventions
- ATRC-101, Pembrolizumab, Pegylated liposomal doxorubicin (PLD)
- Biological · Drug
- Lead sponsor
- Atreca, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 19
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Duarte, California + 15 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 937–960
of 10,873
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Breast Cancer, Breast Neoplasms, Cancer of the Breast
- Interventions
- gemcitabine, docetaxel, capecitabine
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 475 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2008
- U.S. locations
- 47
- States / cities
- Glendale, Arizona • Fort Smith, Arkansas • Hot Springs, Arkansas + 44 more
- Conditions
- Chronic Idiopathic Constipation
- Interventions
- BLI400 Laxative, Lubiprostone
- Drug
- Lead sponsor
- Braintree Laboratories
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 459 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015
- U.S. locations
- 50
- States / cities
- Mobile, Alabama • Tucson, Arizona • Anaheim, California + 40 more
- Conditions
- Breast Cancer
- Interventions
- HCQ, Avelumab, Palbociclib
- Drug
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 7
- States / cities
- Washington D.C., District of Columbia • Chicago, Illinois • Indianapolis, Indiana + 4 more
- Conditions
- Newly Diagnosed Multiple Myeloma
- Interventions
- AZD0120, Daratumumab, Dexamethasone, Isatuximab, Lenalidomide, Bortezomib, Cyclophosphamide, Fludarabine
- Biological · Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 750 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2034
- U.S. locations
- 45
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 37 more
- Conditions
- Influenza
- Interventions
- Trivalent inactivated influenza vaccine, Inactivated H1N1 Vaccine, Placebo
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 805 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 5
- States / cities
- Decatur, Georgia • St Louis, Missouri • Cincinnati, Ohio + 2 more
- Conditions
- Allergic Rhinitis Due to Grass Pollens
- Interventions
- 300 IR, Placebo
- Drug
- Lead sponsor
- Stallergenes Greer
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 473 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 19
- States / cities
- Normal, Illinois • Lexington, Kentucky • Owensboro, Kentucky + 16 more
- Conditions
- Primary Sjögren Syndrome
- Interventions
- RSLV-132, Placebo
- Drug
- Lead sponsor
- Resolve Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years · Female only
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 24
- States / cities
- Chula Vista, California • Tustin, California • Boca Raton, Florida + 20 more
- Conditions
- Contraceptive Usage
- Interventions
- Norethindrone Acetate
- Drug
- Lead sponsor
- Watson Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 1,659 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2012
- U.S. locations
- 53
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 50 more
- Conditions
- Extensive-stage Small Cell Lung Carcinoma, Advanced Small Cell Lung Cancer
- Interventions
- Obrixtamig, Pumitamig, Carboplatin, Etoposide
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 5
- States / cities
- Miami, Florida • Boston, Massachusetts • East Brunswick, New Jersey + 2 more
- Conditions
- Triple-Negative Breast Cancer
- Interventions
- Pembrolizumab, Sacituzumab tirumotecan, Capecitabine
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,530 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2037
- U.S. locations
- 93
- States / cities
- Mobile, Alabama • Chandler, Arizona • Fountain Valley, California + 78 more
- Conditions
- Covid19
- Interventions
- IFN beta-1a, Dexamethasone
- Drug
- Lead sponsor
- Faron Pharmaceuticals Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 4
- States / cities
- Aurora, Colorado • Boston, Massachusetts • Newton, Massachusetts + 1 more
- Conditions
- Advanced Solid Tumor, Pancreatic Adenocarcinoma, Malignant Melanoma (Cutaneous), Non-small Cell Lung Cancer (NSCLC)
- Interventions
- IMM-1-104 Monotherapy (Treatment Group A), IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B), IMM-1-104 + modified FOLFIRINOX (Treatment Group C), IMM-1-104 + dabrafenib (Treatment Group D), IMM-1-104 + pembrolizumab (Treatment Group E)
- Drug
- Lead sponsor
- Immuneering Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 209 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 20
- States / cities
- Scottsdale, Arizona • Duarte, California • San Diego, California + 16 more
- Conditions
- Relapsed/Refractory Systemic Light Chain Amyloidosis
- Interventions
- Linvoseltamab
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2035
- U.S. locations
- 8
- States / cities
- Duarte, California • Denver, Colorado • Boston, Massachusetts + 5 more
- Conditions
- B-cell Follicular Lymphoma, B-cell Marginal Zone Lymphoma, Diffuse Large B-cell Lymphoma, B-cell Mantle Cell Lymphoma, B-cell Small Lymphocytic Lymphoma, B-Cell Chronic Lymphocytic Leukemia, Multiple Myeloma, Waldenstrom's Macroglobulinemia, Noncutaneous Peripheral T-cell Lymphoma Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Enteropathy Associated T-cell Lymphoma, NK Lymphoma
- Interventions
- Alisertib
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2016
- U.S. locations
- 10
- States / cities
- Scottsdale, Arizona • Lexington, Kentucky • Baltimore, Maryland + 7 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Sotatercept, Placebo, Background PAH Therapy
- Biological · Drug
- Lead sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 324 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 39
- States / cities
- Phoenix, Arizona • Tucson, Arizona • San Diego, California + 32 more
- Conditions
- Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Melanoma, Head and Neck Cancer
- Interventions
- CAB-ROR2-ADC, PD-1 inhibitor
- Biological
- Lead sponsor
- BioAtla, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 38
- States / cities
- Tucson, Arizona • Duarte, California • La Jolla, California + 30 more
- Conditions
- Diabetes Mellitus
- Interventions
- Diabetes Care Gaps Patient Portal Intervention
- Other
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 440 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Lymphoma
- Interventions
- Rituximab, Cytarabine, Dexamethasone, Leucovorin, Methotrexate, Procarbazine, Vincristine
- Biological · Drug
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2015
- U.S. locations
- 68
- States / cities
- Stanford, California • Gainesville, Florida • Jacksonville, Florida + 51 more
- Conditions
- Prematurity
- Interventions
- Oral priming
- Other
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- Up to 1 Year
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Cancer
- Interventions
- Regimen A, Regimen B, Regimen C, Regimen D
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 4
- States / cities
- Scottsdale, Arizona • Detroit, Michigan • Nashville, Tennessee + 1 more
- Conditions
- Menorrhagia, Heavy Menstrual Bleeding
- Interventions
- Tranexamic acid tablets (XP12B)
- Drug
- Lead sponsor
- Ferring Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 49 Years · Female only
- Enrollment
- 784 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 59
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 47 more
- Conditions
- Aortic Stenosis
- Interventions
- Medtronic TAV, Edwards TAV
- Device
- Lead sponsor
- Medtronic Cardiovascular
- Industry
- Eligibility
- 18 Years to 105 Years
- Enrollment
- 225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 71
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 58 more
- Conditions
- Type 2 Diabetes Mellitus (T2DM), Type 1 Diabetes Mellitus (T1DM), Hyperglycemia
- Interventions
- Libre 3 Plus Continuous Glucose Monitor, Dexcom G7 Continuous Glucose Monitor
- Device
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee